Online inquiry

IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11975MR)

This product GTTS-WQ11975MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB3&IGF1R gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005915.1; NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2065; 3480
UniProt ID P21860; P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11975MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ6713MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ15670MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ6359MR IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CSL-362-AML
GTTS-WQ6501MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ15013MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ10686MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ3281MR IVTScrip™ mRNA-Anti-alpha toxin&lukE, ASN-1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ9556MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA J6M0
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW